ROBERT E. HOLLINGSWORTH,JOHN W. HARPER, III,EMIL MICHELOTTI,RAYMOND ROTHSTEIN,JONATHAN RIOS-DORIA
申请号：
US16341194
公开号：
US20200023072A1
申请日:
2017.10.10
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention is concerned with antibody-drug conjugates (ADCs) for use in cancer immunotherapy. The invention provides an ADC in combination with an immunotherapy (IMT) agent for use in cancer treatment. For example: The invention provides an ADC for use in cancer immunotherapy, wherein the use comprises administering to a patient the ADC in combination with an IMT agent. The invention also provides an IMT agent for use in cancer immunotherapy, wherein the use comprises administering to a patient the IMT agent in combination with an ADC. The invention provides an ADC and an IMT agent for use in cancer immunotherapy, wherein the use comprises administering to a patient the ADC in combination with the IMT agent. The invention provides an ADC for use in cancer immunotherapy, wherein the use comprises simultaneously, separately or sequentially administering to a patient the ADC in combination with an IMT agent. The invention also provides an IMT agent for use in cancer immunotherapy, wherein the use comprises simultaneously, separately or sequentially administering to a patient the IMT agent in combination with an ADC. The invention provides an ADC and an IMT agent for use in cancer immunotherapy, wherein the use comprises simultaneously, separately or sequentially administering to a patient the ADC in combination with the IMT agent. The invention provides a cancer immunotherapy method, the method comprising administering to a patient an ADC and an IMT agent. The invention provides a cancer immunotherapy method, the method comprising simultaneously, separately or sequentially administering to a patient an ADC and an IMT agent.
